Search tips
Search criteria 


Logo of molmedLink to Publisher's site
Mol Med. 1997 February; 3(2): 96–110.
PMCID: PMC2230055

Inhibition of early and late events of the HIV-1 replication cycle by cytoplasmic Fab intrabodies against the matrix protein, p17.


BACKGROUND: The HIV-1 matrix (MA) protein, p17, contains two subcellular localization signals that facilitate both nuclear import of the viral preintegration complex early during infection and virus particle assembly late in infection. The dual role of MA in both the afferent and efferent arms of the HIV-1 life cycle makes it an important target for intracellular immunization-based gene therapy strategies. MATERIALS AND METHODS: Here we report, using a new bicistronic vector, that an intracellular Fab antibody, or Fab intrabody, directed against a carboxy-terminal epitope of MA from the Clade B HIV-1 genotype, can inhibit HIV-1 infection when expressed in the cytoplasm of actively dividing CD4+ T cells. RESULTS: Marked inhibition of proviral gene expression occurred when single-round HIV-1 CAT virus was used for infections. In challenge experiments using both laboratory strains and syncytium-inducing primary isolates of HIV-1, a substantial reduction in the infectivity of virions released from the cells was also observed. CONCLUSIONS: This novel strategy of simultaneously blocking early and late events of the HIV-1 life cycle may prove useful in clinical gene therapy approaches for the treatment of HIV-1 infection and AIDS, particularly when combined with genetic or pharmacologic-based strategies that inhibit other HIV-1 target molecules simultaneously.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (2.6M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Images in this article

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Baltimore D. Gene therapy. Intracellular immunization. Nature. 1988 Sep 29;335(6189):395–396. [PubMed]
  • Gilboa E, Smith C. Gene therapy for infectious diseases: the AIDS model. Trends Genet. 1994 Apr;10(4):139–144. [PubMed]
  • Marasco WA, Haseltine WA, Chen SY. Design, intracellular expression, and activity of a human anti-human immunodeficiency virus type 1 gp120 single-chain antibody. Proc Natl Acad Sci U S A. 1993 Aug 15;90(16):7889–7893. [PubMed]
  • Marasco WA. Intracellular antibodies (intrabodies) as research reagents and therapeutic molecules for gene therapy. Immunotechnology. 1995 May;1(1):1–19. [PubMed]
  • Chen SY, Khouri Y, Bagley J, Marasco WA. Combined intra- and extracellular immunization against human immunodeficiency virus type 1 infection with a human anti-gp120 antibody. Proc Natl Acad Sci U S A. 1994 Jun 21;91(13):5932–5936. [PubMed]
  • Chen SY, Bagley J, Marasco WA. Intracellular antibodies as a new class of therapeutic molecules for gene therapy. Hum Gene Ther. 1994 May;5(5):595–601. [PubMed]
  • Mhashilkar AM, Bagley J, Chen SY, Szilvay AM, Helland DG, Marasco WA. Inhibition of HIV-1 Tat-mediated LTR transactivation and HIV-1 infection by anti-Tat single chain intrabodies. EMBO J. 1995 Apr 3;14(7):1542–1551. [PubMed]
  • Duan L, Bagasra O, Laughlin MA, Oakes JW, Pomerantz RJ. Potent inhibition of human immunodeficiency virus type 1 replication by an intracellular anti-Rev single-chain antibody. Proc Natl Acad Sci U S A. 1994 May 24;91(11):5075–5079. [PubMed]
  • Maciejewski JP, Weichold FF, Young NS, Cara A, Zella D, Reitz MS, Jr, Gallo RC. Intracellular expression of antibody fragments directed against HIV reverse transcriptase prevents HIV infection in vitro. Nat Med. 1995 Jul;1(7):667–673. [PubMed]
  • Bukrinsky MI, Haggerty S, Dempsey MP, Sharova N, Adzhubel A, Spitz L, Lewis P, Goldfarb D, Emerman M, Stevenson M. A nuclear localization signal within HIV-1 matrix protein that governs infection of non-dividing cells. Nature. 1993 Oct 14;365(6447):666–669. [PubMed]
  • von Schwedler U, Kornbluth RS, Trono D. The nuclear localization signal of the matrix protein of human immunodeficiency virus type 1 allows the establishment of infection in macrophages and quiescent T lymphocytes. Proc Natl Acad Sci U S A. 1994 Jul 19;91(15):6992–6996. [PubMed]
  • Bukrinsky MI, Sharova N, McDonald TL, Pushkarskaya T, Tarpley WG, Stevenson M. Association of integrase, matrix, and reverse transcriptase antigens of human immunodeficiency virus type 1 with viral nucleic acids following acute infection. Proc Natl Acad Sci U S A. 1993 Jul 1;90(13):6125–6129. [PubMed]
  • Sharova N, Bukrinskaya A. p17 and p17-containing gag precursors of input human immunodeficiency virus are transported into the nuclei of infected cells. AIDS Res Hum Retroviruses. 1991 Mar;7(3):303–306. [PubMed]
  • Heinzinger NK, Bukrinsky MI, Haggerty SA, Ragland AM, Kewalramani V, Lee MA, Gendelman HE, Ratner L, Stevenson M, Emerman M. The Vpr protein of human immunodeficiency virus type 1 influences nuclear localization of viral nucleic acids in nondividing host cells. Proc Natl Acad Sci U S A. 1994 Jul 19;91(15):7311–7315. [PubMed]
  • Spearman P, Wang JJ, Vander Heyden N, Ratner L. Identification of human immunodeficiency virus type 1 Gag protein domains essential to membrane binding and particle assembly. J Virol. 1994 May;68(5):3232–3242. [PMC free article] [PubMed]
  • Zhou W, Parent LJ, Wills JW, Resh MD. Identification of a membrane-binding domain within the amino-terminal region of human immunodeficiency virus type 1 Gag protein which interacts with acidic phospholipids. J Virol. 1994 Apr;68(4):2556–2569. [PMC free article] [PubMed]
  • Göttlinger HG, Sodroski JG, Haseltine WA. Role of capsid precursor processing and myristoylation in morphogenesis and infectivity of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A. 1989 Aug;86(15):5781–5785. [PubMed]
  • Pal R, Reitz MS, Jr, Tschachler E, Gallo RC, Sarngadharan MG, Veronese FD. Myristoylation of gag proteins of HIV-1 plays an important role in virus assembly. AIDS Res Hum Retroviruses. 1990 Jun;6(6):721–730. [PubMed]
  • Dorfman T, Mammano F, Haseltine WA, Göttlinger HG. Role of the matrix protein in the virion association of the human immunodeficiency virus type 1 envelope glycoprotein. J Virol. 1994 Mar;68(3):1689–1696. [PMC free article] [PubMed]
  • Yu X, Yuan X, Matsuda Z, Lee TH, Essex M. The matrix protein of human immunodeficiency virus type 1 is required for incorporation of viral envelope protein into mature virions. J Virol. 1992 Aug;66(8):4966–4971. [PMC free article] [PubMed]
  • Yu X, Yu QC, Lee TH, Essex M. The C terminus of human immunodeficiency virus type 1 matrix protein is involved in early steps of the virus life cycle. J Virol. 1992 Sep;66(9):5667–5670. [PMC free article] [PubMed]
  • Bukrinskaya AG, Ghorpade A, Heinzinger NK, Smithgall TE, Lewis RE, Stevenson M. Phosphorylation-dependent human immunodeficiency virus type 1 infection and nuclear targeting of viral DNA. Proc Natl Acad Sci U S A. 1996 Jan 9;93(1):367–371. [PubMed]
  • Gallay P, Swingler S, Aiken C, Trono D. HIV-1 infection of nondividing cells: C-terminal tyrosine phosphorylation of the viral matrix protein is a key regulator. Cell. 1995 Feb 10;80(3):379–388. [PubMed]
  • Gallay P, Swingler S, Song J, Bushman F, Trono D. HIV nuclear import is governed by the phosphotyrosine-mediated binding of matrix to the core domain of integrase. Cell. 1995 Nov 17;83(4):569–576. [PubMed]
  • Bagley J, Dillon PJ, Rosen C, Robinson J, Sodroski J, Marasco WA. Structural characterization of broadly neutralizing human monoclonal antibodies against the CD4 binding site of HIV-1 gp120. Mol Immunol. 1994 Oct;31(15):1149–1160. [PubMed]
  • Marasco WA, Bagley J, Zani C, Posner M, Cavacini L, Haseltine WA, Sodroski J. Characterization of the cDNA of a broadly reactive neutralizing human anti-gp120 monoclonal antibody. J Clin Invest. 1992 Oct;90(4):1467–1478. [PMC free article] [PubMed]
  • Niedrig M, Hinkula J, Weigelt W, L'age-Stehr J, Pauli G, Rosen J, Wahren B. Epitope mapping of monoclonal antibodies against human immunodeficiency virus type 1 structural proteins by using peptides. J Virol. 1989 Aug;63(8):3525–3528. [PMC free article] [PubMed]
  • Göttlinger HG, Dorfman T, Cohen EA, Haseltine WA. Vpu protein of human immunodeficiency virus type 1 enhances the release of capsids produced by gag gene constructs of widely divergent retroviruses. Proc Natl Acad Sci U S A. 1993 Aug 1;90(15):7381–7385. [PubMed]
  • Helseth E, Kowalski M, Gabuzda D, Olshevsky U, Haseltine W, Sodroski J. Rapid complementation assays measuring replicative potential of human immunodeficiency virus type 1 envelope glycoprotein mutants. J Virol. 1990 May;64(5):2416–2420. [PMC free article] [PubMed]
  • Li G, Simm M, Potash MJ, Volsky DJ. Human immunodeficiency virus type 1 DNA synthesis, integration, and efficient viral replication in growth-arrested T cells. J Virol. 1993 Jul;67(7):3969–3977. [PMC free article] [PubMed]
  • Zack JA, Arrigo SJ, Weitsman SR, Go AS, Haislip A, Chen IS. HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell. 1990 Apr 20;61(2):213–222. [PubMed]
  • Duke GM, Hoffman MA, Palmenberg AC. Sequence and structural elements that contribute to efficient encephalomyocarditis virus RNA translation. J Virol. 1992 Mar;66(3):1602–1609. [PMC free article] [PubMed]
  • Louwagie J, McCutchan FE, Peeters M, Brennan TP, Sanders-Buell E, Eddy GA, van der Groen G, Fransen K, Gershy-Damet GM, Deleys R, et al. Phylogenetic analysis of gag genes from 70 international HIV-1 isolates provides evidence for multiple genotypes. AIDS. 1993 Jun;7(6):769–780. [PubMed]
  • Ansari-Lari MA, Donehower LA, Gibbs RA. Analysis of human immunodeficiency virus type 1 integrase mutants. Virology. 1995 Aug 1;211(1):332–335. [PubMed]
  • Engelman A, Englund G, Orenstein JM, Martin MA, Craigie R. Multiple effects of mutations in human immunodeficiency virus type 1 integrase on viral replication. J Virol. 1995 May;69(5):2729–2736. [PMC free article] [PubMed]
  • Lewis P, Hensel M, Emerman M. Human immunodeficiency virus infection of cells arrested in the cell cycle. EMBO J. 1992 Aug;11(8):3053–3058. [PubMed]
  • Sakai H, Kawamura M, Sakuragi J, Sakuragi S, Shibata R, Ishimoto A, Ono N, Ueda S, Adachi A. Integration is essential for efficient gene expression of human immunodeficiency virus type 1. J Virol. 1993 Mar;67(3):1169–1174. [PMC free article] [PubMed]
  • Wiskerchen M, Muesing MA. Human immunodeficiency virus type 1 integrase: effects of mutations on viral ability to integrate, direct viral gene expression from unintegrated viral DNA templates, and sustain viral propagation in primary cells. J Virol. 1995 Jan;69(1):376–386. [PMC free article] [PubMed]
  • Stevenson M, Haggerty S, Lamonica CA, Meier CM, Welch SK, Wasiak AJ. Integration is not necessary for expression of human immunodeficiency virus type 1 protein products. J Virol. 1990 May;64(5):2421–2425. [PMC free article] [PubMed]
  • Willey RL, Maldarelli F, Martin MA, Strebel K. Human immunodeficiency virus type 1 Vpu protein regulates the formation of intracellular gp160-CD4 complexes. J Virol. 1992 Jan;66(1):226–234. [PMC free article] [PubMed]
  • Fenyö EM, Albert J, Asjö B. Replicative capacity, cytopathic effect and cell tropism of HIV. AIDS. 1989;3 (Suppl 1):S5–12. [PubMed]
  • Blomberg J, Medstrand P. A sequence in the carboxyl terminus of the HIV-1 matrix protein is highly similar to sequences in membrane-associated proteins of other RNA viruses: possible functional implications. New Biol. 1990 Nov;2(11):1044–1046. [PubMed]
  • Biocca S, Ruberti F, Tafani M, Pierandrei-Amaldi P, Cattaneo A. Redox state of single chain Fv fragments targeted to the endoplasmic reticulum, cytosol and mitochondria. Biotechnology (N Y) 1995 Oct;13(10):1110–1115. [PubMed]
  • Duan L, Zhang H, Oakes JW, Bagasra O, Pomerantz RJ. Molecular and virological effects of intracellular anti-Rev single-chain variable fragments on the expression of various human immunodeficiency virus-1 strains. Hum Gene Ther. 1994 Nov;5(11):1315–1324. [PubMed]
  • Gelderblom HR, Hausmann EH, Ozel M, Pauli G, Koch MA. Fine structure of human immunodeficiency virus (HIV) and immunolocalization of structural proteins. Virology. 1987 Jan;156(1):171–176. [PubMed]
  • Bukrinsky MI, Sharova N, Dempsey MP, Stanwick TL, Bukrinskaya AG, Haggerty S, Stevenson M. Active nuclear import of human immunodeficiency virus type 1 preintegration complexes. Proc Natl Acad Sci U S A. 1992 Jul 15;89(14):6580–6584. [PubMed]
  • Lewis PF, Emerman M. Passage through mitosis is required for oncoretroviruses but not for the human immunodeficiency virus. J Virol. 1994 Jan;68(1):510–516. [PMC free article] [PubMed]
  • Roe T, Reynolds TC, Yu G, Brown PO. Integration of murine leukemia virus DNA depends on mitosis. EMBO J. 1993 May;12(5):2099–2108. [PubMed]
  • Lodge R, Göttlinger H, Gabuzda D, Cohen EA, Lemay G. The intracytoplasmic domain of gp41 mediates polarized budding of human immunodeficiency virus type 1 in MDCK cells. J Virol. 1994 Aug;68(8):4857–4861. [PMC free article] [PubMed]
  • Morikawa Y, Kishi T, Zhang WH, Nermut MV, Hockley DJ, Jones IM. A molecular determinant of human immunodeficiency virus particle assembly located in matrix antigen p17. J Virol. 1995 Jul;69(7):4519–4523. [PMC free article] [PubMed]
  • Freed EO, Orenstein JM, Buckler-White AJ, Martin MA. Single amino acid changes in the human immunodeficiency virus type 1 matrix protein block virus particle production. J Virol. 1994 Aug;68(8):5311–5320. [PMC free article] [PubMed]
  • Choo V. Combination superior to zidovudine in Delta trial. Lancet. 1995 Sep 30;346(8979):895–895. [PubMed]

Articles from Molecular Medicine are provided here courtesy of The Feinstein Institute for Medical Research at North Shore LIJ